A Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel, Phase II Clinical Trial to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO in Patients Undergoing Colon Resection
Latest Information Update: 08 Apr 2014
At a glance
- Drugs LD02GIFRO (Primary)
- Indications Postoperative ileus
- Focus Therapeutic Use
- Sponsors LG Life Sciences
Most Recent Events
- 08 Apr 2014 New trial record